Mark Feldstein, Ph.D., is a partner with Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. His practice focuses on U.S. district court litigation, primarily concerning the enforcement of U.S. patent rights and trade secret issues, and post-grant trial proceedings at the U.S. Patent and Trademark Office (USPTO), including inter partes review (IPR) and post grant review (PGR). He has particular experience with litigations arising from Abbreviated New Drug Applications (ANDAs) under the Hatch-Waxman Act. Mark’s practice encompasses a range of technologies, including pharmaceuticals, chemicals, biochemistry, polymers, small molecule chemistry, nanotechnology, optics, and medical and analytic devices. His proficiency in these areas is supported by extensive graduate-level and post-doctoral research experience. Mark is also an adjunct professor of law at Georgetown University Law Center, teaching courses in patent prosecution strategy. He speaks regularly to national and international audiences of both attorneys and scientists on issues of patent strategy, prosecution, and litigation. Mark serves as an associate editor for texts published by the American Bar Association Section of Intellectual Property Law on Abbreviated New Drug Application (ANDA) litigation law and strategy, and by AIPLA/Bloomberg BNA on evidence in patent litigations.